Department of Error

Hurvitz SA, Hegg R, Chung W-P, et al Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105–17—In figure 1 of this Article, the number at risk in the trastuzumab emtansine group at month 0 in panel B should have been 263, and the appendix has been updated. This correction has been made to the online version as of Feb 16, 2023.